HPK1-IN-2 didrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 µΜ) with antitumor activity. HPK1-IN-2 didrochloride also inhibits Lck (0.05 µΜ<IC50<0.5 µΜ) and Flt3 (IC50<0.05 µΜ) kinase activities.
In a-CD3 stimulated Jurkat E6. 1 cells, HPK1-IN-2 (example A1) inhibits SLP76 serine 376 phosphorylation and ERK1/2 T202/Y204 phosphorylation with IC50 values of 0.3-1 µΜ and >3µΜ, respectively[1].
HPK1-IN-2 (example A1; 75-150 mg/kg; oral gavage; daily; for 21 days) treatment shows a dose-dependently tumor growth inhibition, with 75 mg/kg and 150 mg/kg QD inhibiting tumour growth by 44% and 64%, respectively[1].
References:
[1]. Peter Brent Sampson, et al. Hpk1 inhibitors and methods of using same. WO2016205942A1.